Page 560 - Williams Hematology ( PDFDrive )

534 Part VI: The Erythrocyte Chapter 35: Aplastic Anemia: Acquired and Inherited 535

135. Horsley SW, Colman S, McKinley M, et al: Genetic lesions in a preleukemic aplasia 168. Garg R, Faderl S, Garcia-Manero G, et al: Phase II study of rabbit anti-thymocyte glob-
phase in a child with acute lymphoblastic leukemia. Genes Chromosomes Cancer 47:333, ulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic
2008. anemia and myelodysplastic syndrome. Leukemia 23:1297, 2009.
136. Suzan F, Terré C, Garcia I, et al: Three cases of typical aplastic anaemia associated with 169. Scheinberg P, Nunez O, Weinstein B, et al: Horse versus rabbit antithymocyte globulin
a Philadelphia chromosome. Br J Haematol 112:385, 2001. in acquired aplastic anemia. N Engl J Med 365:430, 2011.
137. Socie G, Rosenfeld S, Frickhofen N, et al: Late clonal diseases of aplastic anemia. Semin 170. Kadia TM, Borthakur G, Garcia-Manero G, et al: Final results of the phase II study
Hematol 37:91–101 2000. of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte
138. Gordon-Smith EC, Marsh JC, Gibson FM: Views on the pathophysiology of aplastic colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syn-
anemia. Int J Hematol 76(Suppl 2):163, 2002. drome. Br J Haematol 157:312, 2012.
139. Maciejewski JP, Risitano A, Sloand EM, et al: Distinct clinical outcomes for cytogenetic 171. Afable MG 2nd, Shaik M, Sugimoto Y, et al: Efficacy of rabbit anti-thymocyte globulin
abnormalities evolving from aplastic anemia. Blood 99:3129, 2002. in severe aplastic anemia. Haematologica 96: 2069, 2011.
140. Socie G, Henryamar M, Bacigalupo A, et al: Malignant tumors occurring after treat- 172. Chen, C, Xue HM, Li Y, et al: Rabbit-antithymocyte globulin combined with cyclospo-
ment of aplastic anemia. N Engl J Med 329:1152, 1993. rine A as a first-line therapy: Improved, effective and safe for children with acquired
141. Najean Y, Haguenauer O: Long-term (5–20 years) evolution of non-grafted aplastic severe aplastic anemia. J Cancer Res Clin Oncol 138:1105, 2012.
anemias. Blood 76:2222, 1990. 173. Marsh JC, Bacigalupo A, Schrezenmeier H, et al: Prospective study of rabbit antithy-
142. Ball SE, Gibson FM, Rizzo S: Progressive telomere shortening in aplastic anemia. Blood mocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic
91:3582, 1998. Anaemia Working Party. Blood 119:5391, 2012.
143. Rosse WF: New insights into paroxysmal nocturnal hemoglobinuria. Curr Opin Hema- 174. Shin SH, Yoon JH, Yahng SA, et al: The efficacy of rabbit antithymocyte globulin with
tol 8:61, 2001. cyclosporine in comparison to horse antithymocyte globulin as a first-line treatment
144. Nakakuma H, Kawaguchi T: Pathogenesis of selective expansion of PNH clones. Int J in adult patients with severe aplastic anemia: A single-center retrospective study. Ann
Hematol 77:121, 2003. Hematol 92:817, 2013.
145. Scheinberg P, Marte M, Nunez O, Young NS: Paroxysmal nocturnal hemoglobinuria 175. Camitta B, O’Reilly RJ, Sensenbrenner L: Antithoracic duct lymphocyte globulin ther-
clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin apy of severe aplastic anemia. Blood 62:883, 1983.
plus cyclosporine. Haematologica 95:1075, 2010. 176. Champlin R, Ho W, Gale RP: Antithymocyte globulin treatment in patients with aplas-
146. Storb R, Blume KG, O’Donnell MR, et al: Cyclophosphamide and antithymocyte glob- tic anemia: A prospective randomized trial. N Engl J Med 308:113, 1983.
ulin to condition patients with aplastic anemia for allogeneic marrow transplantation: 177. Young N, Griffin P, Brittain E, et al: A multicenter trial of antithymocyte globulin in
The experience in four centers. Biol Blood Marrow Transplant 7:39, 2001. aplastic anemia and related diseases. Blood 72:1861, 1988.
147. Metzgeroth G, Dinter D, Schultheis B, et al: Deferasirox in MDS patients with transfu- 178. Schrezenmeier H, Marin P, Raghavachar A, et al: Relapse of aplastic anaemia after
sion-caused iron overload-a phase-II study. Ann Hematol 88:301, 2009. immunosuppressive treatment: A report from the European Bone Marrow Transplan-
148. Sagmeister M, Oec L, Gmur J: A restrictive platelet transfusion policy allowing long- tation Group SAA Working Party. Br J Haematol 85:371, 1993.
term support of outpatients with severe aplastic anemia. Blood 93:3124, 1999. 179. Doney K, Leisenring W, Storb R, Appelbaum FR: Primary treatment of acquired aplas-
149. Lawrence JB, Yomtovian RA, Hammons T, et al: Lowering the prophylactic platelet tic anemia: Outcomes with bone marrow transplantation and immunosuppressive
transfusion threshold: A prospective analysis. Leuk Lymphoma 41:67, 2001. therapy. Ann Intern Med 126:107, 1997.
150. Zeigler ZR: Effects of epsilon aminocaproic acid on primary haemostasis. Haemostasis 180. Tichelli A, Gratwohl A, Nissen C, Speck B: Late clonal complications in severe aplastic
21:313, 1991. anemia. Leuk Lymphoma 12:167, 1994.
151. Hod E, Schwartz J: Platelet transfusion refractoriness. Br J Haematol 142:348, 2008. 181. De Planque MM, Bacigalupo A, Würsch A, et al: Long-term follow-up of severe aplastic
152. Slichter SJ, Davis K, Enright H, et al: Factors affecting posttransfusion platelet incre- anaemia patients treated with antithymocyte globulin. Br J Haematol 73:121, 1989.
ments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic 182. Socié G, Henry-Amar M, Bacigalupo A, et al: Malignant tumors occurring after treat-
patients. Blood 105:4106, 2005. ment of aplastic anemia. N Engl J Med 319:1152, 1993.
153. Drewniak A, Boelens JJ, Vrielink H, et al: Granulocyte concentrates: Prolonged func- 183. Calado RT, Cooper JN, Padilla-Nash HM, et al: Short telomeres result in chromosomal
tional capacity during storage in the presence of phenotypic changes. Haematologica instability in hematopoietic cells and precede malignant evolution in human aplastic
93:1058, 2008. anemia. Leukemia 26:700, 2012.
154. Armand P, Antin JH: Allogeneic stem cell transplantation for aplastic anemia. Biol 184. Stryckmans PA, Dumont JP, Velu T, Debusscher L: Cyclosporine in refractory severe
Blood Marrow Transplant 13:505, 2007. aplastic anemia [letter]. N Engl J Med 310:655, 1984.
155. Georges GE, Storb R: Stem cell transplantation for aplastic anemia. Int J Hematol 185. Lazzarino M, Morra E, Canevari A, et al: Cyclosporine in the treatment of aplastic
75:141, 2002. anaemia and pure red-cell aplasia. Bone Marrow Transplant 4(Suppl 4):165, 1989.
156. Champlin RE, Perez WS, Passweg JR, et al: Bone marrow transplantation for severe 186. Hinterberger-Fischer M, Höcker P, Lechner K, et al: Oral cyclosporin-A is effective
aplastic anemia: A randomized controlled study of conditioning regimens. Blood treatment for untreated and also for previously immunosuppressed patients with severe
109:4582, 2007. bone marrow failure. Eur J Haematol 43:136, 1989.
157. Locasciulli A, Oneto R, Bacigalupo A, et al: Outcome of patients with acquired aplastic 187. Tötterman TH, Höglund M, Bengtsson M, et al: Treatment of pure red-cell aplasia and
anemia given first line bone marrow transplantation or immunosuppressive treatment aplastic anaemia with cyclosporin: Long-term clinical effects. Eur J Haematol 42:126,
in the last decade: A report from the European Group for Blood and Marrow Trans- 1989.
plantation (EBMT). Haematologica 92:11, 2007. 188. Leeksma OC, Thomas LLM, van der Lelie J, et al: Effectiveness of low dose cyclosporine
158. Gandhi S, Kulasekararaj AG, Mufti GJ, Marsh JC: Allogeneic stem cell transplanta- in acquired aplastic anaemia with severe neutropenia. Neth J Med 41:143, 1992.
tion using alemtuzumab-containing regimens in severe aplastic anemia. Int J Hematol 189. Leonard EM, Raefsky E, Griffith P, et al: Cyclosporine therapy of aplastic anaemia, con-
97:573, 2013. genital and acquired red-cell aplasia. Br J Haematol 72:278, 1989.
159. Viollier R, Socié G, Tichelli A, et al: Recent improvement in outcome of unrelated 190. Tong J, Bacigalupo A, Piaggio G, et al: Severe aplastic anemia (SAA): Response to cyclo-
donor transplantation for aplastic anemia. Bone Marrow Transplant 41:45, 2008. sporin A (CyA) in vivo and in vitro. Eur J Haematol 46:212, 1991.
160. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, et al: High-resolution donor-recipient 191. Nakao S, Yamaguchi M, Shiobara S, et al: Interferon-g gene expression in unstimulated
HLA matching contributes to the success of unrelated donor marrow transplantation. bone marrow mononuclear cells predicts a good response to cyclosporine therapy in
Blood 110:4576, 2007. aplastic anemia. Blood 79:2531, 1992.
161. Dubey S, Nityanand S: Involvement of Fas and TNF pathways in the induction of apop- 192. Kojima S, Fukada M, Miyajima Y, Matsuyama T: Cyclosporine and recombinant
tosis of T cells by antithymocyte globulin. Ann Hematol 82:496, 2003. granulocyte colony-stimulating factor in severe aplastic anemia [letter]. N Engl J Med
162. Michallet M-C, Saltel F, Preville X, et al: Cathepsin-B-dependent apoptosis triggered 313:920, 1990.
by antithymocyte globulins: A novel mechanism of T-cell depletion. Blood 102:3719, 193. Bertrand Y, Amri F, Capdeville R, et al: The successful treatment of two cases of severe
2003. aplastic anaemia with granulocyte colony-stimulating factor and cyclosporine A [case
163. Mangan KF, D’Alessandro L, Mullaney MT: Action of antithymocyte globulin on nor- report]. Br J Haematol 79:648, 1991.
mal human erythroid progenitor cell proliferation in vitro: Erythropoietic growth-en- 194. Schrezenmeier H, Schlander M, Raghavachar A: Cyclosporin A in aplastic anemia—
hancing factors are released from marrow accessory cells. J Lab Clin Med 107:353, 1986. Report of a workshop. Ann Hematol 65:33, 1992.
164. Kawano Y, Nissen C, Gratwohl A, Speck B: Immunostimulatory effects of different ant- 195. Gluckman E, Esperou-Bourdeau H, Baruchel A, et al: Multicenter randomized study
ilymphocyte globulin preparations: A possible clue to their clinical effect. Br J Haematol comparing cyclosporine-A alone and antithymocyte globulin with prednisone for
68:115, 1988. treatment of severe aplastic anemia. Blood 79:2540, 1992.
165. Bielory L, Wright R, Nienhuis AW, et al: Antithymocyte globulin hypersensitivity in 196. Rosenfeld S, Follmann D, Nunez O, et al: Antithymocyte globulin and cyclosporine
bone marrow failure patients. JAMA 260:3164, 1988. for severe aplastic anemia: Association between hematologic response and long-term
166. Zheng Y, Liu Y, Chu Y: Immunosuppressive therapy for acquired severe aplastic ane- outcome. JAMA 289:1130, 2003.
mia (SAA): A prospective comparison of four different regimens. Exp Hematol 34:826, 197. Scheinberg P, Wu CO, Nunez O, et al: Long-term outcome of pediatric patients with
2006. severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr
167. Atta EH, Dias DS, Marra VL, de Azevedo AM: Comparison between horse and rabbit 153:814, 2008.
antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: 198. Osugi Y, Yagasaki H, Sako M, et al: Antithymocyte globulin and cyclosporine for treatment
A single-center retrospective study. Ann Hematol 89:851, 2010. of 44 children with hepatitis associated aplastic anemia. Haematologica 92:1687, 2007.

Kaushansky_chapter 35_p0513-0538.indd 535 9/19/15 12:24 AM